Senores Pharmaceuticals to acquire 2.97% stake in Havix

11 Jul 2025 Evaluate

Senores Pharmaceuticals has entered into the Share Purchase Agreement (SPA) with one of the shareholders (Public Category) of Havix Group Inc. D/B/A Aavis Pharmaceuticals (Havix) for acquisition of 6730 equity shares of Havix i.e. 2.97% of the total paid up share capital of Havix and subject to the terms and conditions as mentioned in the SPA. 

Further, post the aforesaid acquisition the aggregate shareholding of the company (along with the shareholding of its wholly owned subsidiary - Senores Pharmaceuticals Inc.) in Havix will increase from 70.07% to 73.04%. 

The Management Committee of Board of Directors of the company, in their meeting held July 10, 2025, has approved the same.

Havix is a US based company engaged in the business of developing, manufacturing and supplying of various finished formulations. 

Senores Pharmaceuticals is global research driven pharmaceutical company engaged in developing and manufacturing a wide range of generic pharmaceutical products in the B2B segment predominantly for the Regulated Markets across various therapeutic areas and dosage forms.

Senores Pharmaceutic Share Price

777.40 -6.85 (-0.87%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×